Result of AngloGold Ashanti plc’s General Meeting July 24, 2026 AngloGold Ashanti plc (the “Company”) (NYSE: AU; JSE: ANG) today announces the result of the general meeting of its shareholders held at 9:00am (Mountain Daylight Time) on Thursday, 23 July 2026 (the “General Meeting”). The full text of the resolution proposed at the General Meeting is set out in the notice of General Meeting (the [...]
U.K. Enterprises Adopt AI-Augmented Operations July 24, 2026 Organizations prioritize governed AI, employee experience and measurable productivity outcomes as workplace transformation matures, ISG Provider Lens® report says
Comsysto Reply Supports Audi in Evolving Its B2B Used Car Platform With an AI-Based Multi-Agent System July 24, 2026 Comsysto Reply, the Reply Group company specialised in agile software development and cloud-native solutions, has partnered with Audi on the ongoing development of its “Used Car Platform”, the company’s central digital marketplace for B2B used car trading. A tailored multi-agent solution accelerates software development, reduces repetitive activities, and enables faster delivery of new features. This [...]
NADclinic and GCLS Announce Strategic Collaboration in Longevity and Performance Medicine Education July 24, 2026 International collaboration to expand clinician education, professional standards and responsible adoption across longevity and performance medicine
Almirall H1 2026 Results July 24, 2026 Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution. The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth. Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets. The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM). Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026. Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions. Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer July 23, 2026 Steve Marso, M.D., joins Verdiva as CMO from Metsera, where he held the equivalent position, bringing valuable clinical and regulatory expertise as Verdiva continues development of a unique portfolio of once-weekly oral treatments for obesity Also from Metsera, Jason Mallory joins Verdiva as SVP, Clinical Development to lead Verdiva’s clinical trial design and execution
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds July 23, 2026 Largest fundraise in the firm’s history brings total capital raised to more than $75 billion
Allegion (NYSE: ALLE) Reports Q2-2026 Financial Results July 23, 2026 Low-Double Digit Revenue Growth, High-Teens EPS Growth; Raising Full-Year 2026 Outlook Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $2.15, up 16.2% compared with $1.85; Adjusted EPS of $2.40, up 17.6% compared with $2.04 Revenues of $1,151.5 million, up 12.7% on a reported basis and up 6.9% on an organic basis Operating margin of 22.1%, compared with 21.5%; Adjusted operating margin of 24.2%, compared with 23.7%
Trusted Data Transfer at Mission Speed Enables Operations During UK Army’s Rhino Bizz Exercise July 23, 2026 Everfox Cross Domain Technology Reduced Secure Mission-Critical Data Movement to Mere Seconds
Experian accelerates AI-first experiences with ServiceNow AI Platform July 23, 2026 Strategic partnership and platform integration fuels AI driven employee onboarding, third-party risk management, and governance.
